Dinesh Patel - Protagonist Therapeutics President CEO, Director
| PTGX Stock | USD 31.94 2.33 7.87% |
CEO
Dr. Dinesh V. Patel, Ph.D. serves as President, Chief Executive Officer, Director of the Company. He has served as a member of the Companys board of directors and as the Companys President and Chief Executive Officer since December 2008. Dr. Patel has more than 30 years of executive, entrepreneurial and scientific experience spanning the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining the Company, Dr. Patel served from 2006 to 2008 as the President and Chief Executive Officer of Arte Therapeutics, a privately held company focused on the development of drugs for metabolic syndrome. Prior to that, he was the President and Chief Executive Officer of Miikana Therapeutics, an oncologybased company, from 2003 until it was acquired by Entremed in 2005. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor, from 1996 to 2003, most recently as Senior Vice President of Drug Discovery and Licensing. Prior to Vicuron, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax, from 1993 to 1996. Dr. Patel was a medicinal chemist at BristolMyers Squibb from 1985 to 1993 since 2019.
| Age | 67 |
| Tenure | 5 years |
| Professional Marks | Ph.D |
| Address | 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160 |
| Phone | 510 474 0170 |
| Web | https://www.protagonist-inc.com |
Dinesh Patel Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dinesh Patel against Protagonist Therapeutics stock is an integral part of due diligence when investing in Protagonist Therapeutics. Dinesh Patel insider activity provides valuable insight into whether Protagonist Therapeutics is net buyers or sellers over its current business cycle. Note, Protagonist Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Protagonist Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dinesh Patel over two months ago Payment of 3717 shares by Dinesh Patel of Protagonist Therapeutics subject to Rule 16b-3 | ||
Dinesh Patel over three months ago Acquisition by Dinesh Patel of 84875 shares of Protagonist Therapeutics subject to Rule 16b-3 | ||
Dinesh Patel over three months ago Sale by Dinesh Patel of 75000 shares of Protagonist Therapeutics | ||
Dinesh Patel over six months ago Exercise or conversion by Dinesh Patel of 6000 shares of Protagonist Therapeutics subject to Rule 16b-3 |
Protagonist Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.2138 % which means that it generated a profit of $0.2138 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4175 %, meaning that it created $0.4175 on every $100 dollars invested by stockholders. Protagonist Therapeutics' management efficiency ratios could be used to measure how well Protagonist Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.23 in 2024. Return On Capital Employed is likely to drop to -0.29 in 2024. Other Current Assets is likely to rise to about 14.7 M in 2024, whereas Total Assets are likely to drop slightly above 204.1 M in 2024.Similar Executives
| Found 12 records | CEO Age | ||
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Raju Mohan | Ventyx Biosciences | 66 | |
| Robert Coffin | Replimune Group | 59 | |
| Daniel MBA | Acumen Pharmaceuticals | 53 | |
| David PharmD | Verona Pharma PLC | 60 | |
| Amy MBA | Terns Pharmaceuticals | 53 | |
| Andrew MD | Akero Therapeutics | 57 | |
| John Houston | Arvinas | 64 | |
| Sarah Boyce | Avidity BiosciencesInc | 52 | |
| Mark Goldsmith | Revolution Medicines | 62 | |
| Paula Ragan | X4 Pharmaceuticals | 54 | |
| MBA Renaud | Cerevel Therapeutics Holdings | 55 | |
Management Performance
| Return On Equity | 0.42 | ||||
| Return On Asset | 0.21 |
Protagonist Therapeutics Leadership Team
Elected by the shareholders, the Protagonist Therapeutics' board of directors comprises two types of representatives: Protagonist Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protagonist. The board's role is to monitor Protagonist Therapeutics' management team and ensure that shareholders' interests are well served. Protagonist Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protagonist Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mohammad Masjedizadeh, Executive Officer | ||
| Abha Bommireddi, Executive Management | ||
| Ashok Bhandari, Vice President - Chemistry | ||
| Matthew Gosling, Executive Counsel | ||
| Richard Shames, Chief Medical Officer | ||
| Dinesh Patel, President CEO, Director | ||
| David Liu, Chief Scientific Officer, Head of Research & Development | ||
| Carena Spivey, Senior Resources | ||
| Suneel Gupta, Executive Vice President of Clinical Operations and Clinical Pharmacology | ||
| Mark Smythe, Vice President -Technology & Alliances | ||
| Scott MD, Executive Gastroenterology | ||
| FACP MD, Chief Officer | ||
| Carter King, Executive Development | ||
| Asif Ali, Executive Officer |
Protagonist Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protagonist Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.42 | ||||
| Return On Asset | 0.21 | ||||
| Profit Margin | 0.51 % | ||||
| Operating Margin | 0.81 % | ||||
| Current Valuation | 1.33 B | ||||
| Shares Outstanding | 58.65 M | ||||
| Shares Owned By Insiders | 1.24 % | ||||
| Shares Owned By Institutions | 98.76 % | ||||
| Number Of Shares Shorted | 3.73 M | ||||
| Price To Earning | (4.81) X |
Protagonist Therapeutics Investors Sentiment
The influence of Protagonist Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Protagonist. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Protagonist Therapeutics' public news can be used to forecast risks associated with an investment in Protagonist. The trend in average sentiment can be used to explain how an investor holding Protagonist can time the market purely based on public headlines and social activities around Protagonist Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Protagonist Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Protagonist Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Protagonist Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Protagonist Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protagonist Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protagonist Therapeutics' short interest history, or implied volatility extrapolated from Protagonist Therapeutics options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protagonist Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.Note that the Protagonist Therapeutics information on this page should be used as a complementary analysis to other Protagonist Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Protagonist Stock analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Protagonist Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagonist Therapeutics. If investors know Protagonist will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagonist Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 2.54 | Revenue Per Share 5.308 | Quarterly Revenue Growth (1.00) | Return On Assets 0.2138 | Return On Equity 0.4175 |
The market value of Protagonist Therapeutics is measured differently than its book value, which is the value of Protagonist that is recorded on the company's balance sheet. Investors also form their own opinion of Protagonist Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagonist Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagonist Therapeutics' market value can be influenced by many factors that don't directly affect Protagonist Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagonist Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagonist Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagonist Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.